CTXR Strangle Strategy
CTXR (Citius Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS).
CTXR (Citius Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.0M, a beta of 0.98 versus the broader market, a 52-week range of 0.476-2.48, average daily share volume of 663K, a public-listing history dating back to 2014, approximately 23 full-time employees. These structural characteristics shape how CTXR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.98 places CTXR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on CTXR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CTXR snapshot
As of June 30, 2026, spot at $0.60, ATM IV 17.50%, IV rank 0.00%, expected move 5.02%. The strangle on CTXR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on CTXR specifically: CTXR IV at 17.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a CTXR strangle, with a market-implied 1-standard-deviation move of approximately 5.02% (roughly $0.03 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CTXR expiries trade a higher absolute premium for lower per-day decay. Position sizing on CTXR should anchor to the underlying notional of $0.60 per share and to the trader's directional view on CTXR stock.
CTXR strangle setup
The CTXR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CTXR near $0.60, the first option leg uses a $0.63 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CTXR chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CTXR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.63 | N/A |
| Buy 1 | Put | $0.57 | N/A |
CTXR strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CTXR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CTXR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CTXR
Strangles on CTXR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTXR chain.
CTXR thesis for this strangle
The market-implied 1-standard-deviation range for CTXR extends from approximately $0.57 on the downside to $0.63 on the upside. A CTXR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CTXR IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CTXR at 17.50%. As a Healthcare name, CTXR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CTXR-specific events.
CTXR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CTXR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CTXR alongside the broader basket even when CTXR-specific fundamentals are unchanged. Always rebuild the position from current CTXR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CTXR?
- A strangle on CTXR is the strangle strategy applied to CTXR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CTXR stock trading near $0.60, the strikes shown on this page are snapped to the nearest listed CTXR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CTXR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CTXR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 17.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CTXR strangle?
- The breakeven for the CTXR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CTXR market-implied 1-standard-deviation expected move is approximately 5.02%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CTXR?
- Strangles on CTXR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTXR chain.
- How does current CTXR implied volatility affect this strangle?
- CTXR ATM IV is at 17.50% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.